NEW YORK (GenomeWeb News) – Curie-Cancer today announced two three-year partnerships between Institute Curie and French biotech firm Meiogenix to further develop that firm's meiotic recombination technology.

Under the terms of the deals, the technology called SpiX, short for Spo11-based technology, will be used in yeast and mice "to exploit the unexplored natural biodiversity of organisms."

Financial and other terms of the deals were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.